3.11
49.27%
1.06
Aclaris Therapeutics Inc stock is traded at $3.11, with a volume of 16.13M.
It is up +49.27% in the last 24 hours and up +157.14% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
See More
Previous Close:
$2.05
Open:
$2.43
24h Volume:
16.13M
Relative Volume:
20.58
Market Cap:
$202.86M
Revenue:
$31.25M
Net Income/Loss:
$-88.48M
P/E Ratio:
-2.0065
EPS:
-1.55
Net Cash Flow:
$-79.63M
1W Performance:
+16.35%
1M Performance:
+157.14%
6M Performance:
+157.14%
1Y Performance:
+220.65%
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ACRS | 3.05 | 202.86M | 31.25M | -88.48M | -79.63M | -1.55 |
TMO | 500.44 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
DHR | 229.81 | 165.90B | 23.74B | 3.89B | 4.98B | 7.93 |
A | 126.20 | 36.48B | 6.50B | 1.41B | 1.42B | 3.82 |
IDXX | 421.38 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
IQV | 190.51 | 34.31B | 15.32B | 1.41B | 1.96B | 5.95 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-14-22 | Initiated | Stifel | Buy |
Dec-01-22 | Initiated | Goldman | Buy |
Oct-06-22 | Initiated | BTIG Research | Buy |
Jul-23-21 | Resumed | Jefferies | Buy |
Jun-15-21 | Initiated | Piper Sandler | Overweight |
Apr-21-21 | Initiated | H.C. Wainwright | Buy |
Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
May-06-19 | Initiated | SVB Leerink | Outperform |
Mar-28-18 | Resumed | Leerink Partners | Outperform |
Feb-09-18 | Initiated | Guggenheim | Buy |
Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
Nov-29-16 | Initiated | Leerink Partners | Outperform |
Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
Jun-10-16 | Initiated | Guggenheim | Buy |
Nov-02-15 | Initiated | Citigroup | Buy |
Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential - Digital More
Aclaris secures $80 million in private stock sale - Investing.com
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - The Manila Times
Aclaris Therapeutics Announces $80 Million Private Placement - GlobeNewswire
Aclaris Therapeutics Announces Exclusive, Global License - GlobeNewswire
Citadel Advisors LLC Adjusts Position in Aclaris Therapeutics Inc - GuruFocus.com
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Hold at StockNews.com - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Position Boosted by BML Capital Management LLC - MarketBeat
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week - Simply Wall St
News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts - Yahoo Finance
Aclaris stock touches 52-week high at $2.68 amid market fluctuations By Investing.com - Investing.com South Africa
Aclaris stock touches 52-week high at $2.68 amid market fluctuations - Investing.com
FY2024 EPS Estimates for ACRS Reduced by Leerink Partnrs - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by StockNews.com - Defense World
Aclaris Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 - MyChesCo
Aclaris Therapeutics Reports Positive Q3 2024 Milestones - TipRanks
Aclaris: Q3 Earnings Snapshot - The Washington Post
Aclaris Therapeutics Inc earnings missed by $0.10, revenue topped estimates - Investing.com India
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewswire
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Cross Above 50-Day Moving AverageWhat's Next? - MarketBeat
Contrasting Star Equity (NASDAQ:STRR) and Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc - Yahoo Finance
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLC - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Target Price from Analysts - MarketBeat
Stonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MSN
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
Accenture (NYSE:ACN) PT Raised to $365.00 - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World
Investing in Astrazeneca plc ADR (AZN) Is Getting More Attractive - Knox Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
Metric Deep Dive: Understanding Accenture plc (ACN) Through its Ratios - The Dwinnex
American Century Companies Inc. Boosts Stock Position in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial - Clinical Trials Arena
Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily
Accel Entertainment CEO sells shares worth over $49,000 By Investing.com - Investing.com UK
Arch Capital Group (ACGL) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclaris Therapeutics Inc Stock (ACRS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
Leonard Braden Michael | 10% Owner |
Jul 05 '24 |
Buy |
1.15 |
123,017 |
141,334 |
13,447,969 |
Leonard Braden Michael | 10% Owner |
Jul 02 '24 |
Buy |
1.14 |
86,092 |
98,489 |
13,181,664 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):